Endocrinology
News
New drug, finerenone, approved for slowing kidney disease in diabetes
Finerenone (Kerendia) is the first agent approved from a novel class, the nonsteroidal mineralocorticoid receptor antagonists. But its role in...
Conference Coverage
Nocturnal hypoglycemia halved with insulin degludec vs. glargine
Researchers pitted degludec against glargine U100 in the toughest patients with type 1 diabetes, those who had severe nocturnal hypoglycemia.
Conference Coverage
SUSTAIN FORTE: Higher-dose semaglutide safely boosts glycemic control, weight loss
For patients with type 2 diabetes, doubling the weekly semaglutide dose modestly improved glycemic control and weight loss while maintaining...
Conference Coverage
Unmanaged diabetes, high blood glucose tied to COVID-19 severity
Findings suggest in part that hospitalized COVID-19 patients need aggressive treatment of hyperglycemia, regardless of the diagnosis of diabetes...
From the Journals
Sotagliflozin use in T2D patients linked with posthospitalization benefits in analysis
The paper’s outcome measure may be a meaningful, patient-centered way of capturing disease burden, according to the authors.
Conference Coverage
What’s behind brain fog in treated hypothyroidism?
A large survey is believed to be the first to explore the common phenomenon and identify potential avenues of treatment.
Conference Coverage
Medically suspect criterion can determine bariatric surgery coverage
Conference Coverage
Bariatric surgery’s cardiovascular benefit extends to 7 years
From the Journals
Healthy with obesity? The latest study casts doubt
Analysis from the U.K. Biobank finds that persons with “metabolically healthy obesity” still have increased risks for several adverse outcomes,...
News
FDA: More metformin extended-release tablets recalled
Guidelines
AHA: Physical activity best first-line for high BP, cholesterol
Advice to sit less and move more is a critical component of first-line treatment for patients with mild to moderate hypertension and elevated...